Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Sep;72(9):e31875.
doi: 10.1002/pbc.31875. Epub 2025 Jun 24.

Evaluation of TRPA1 as a Therapeutic Target in MYCN-Amplified Neuroblastoma

Alexandra Seger  1 , Dora Adamič  1 , Erick Muciño Olmos  1 , Johannes Nilsson  1 , Sofia Granados-Aparici  2 , Isaac Vieco-Marti  2 , Javanshir Esfandyari  1 , Matilda Engström  1 , Julia Martinez  1 , Adriana Mañas  3   4 , Samuel Navarro  2 , Rosa Noguera  2 , Kristina Aaltonen  1 , Daniel Bexell  1
Affiliations

Evaluation of TRPA1 as a Therapeutic Target in MYCN-Amplified Neuroblastoma

Alexandra Seger et al. Pediatr Blood Cancer. 2025 Sep.

Abstract

Background: Neuroblastoma (NB) is a childhood cancer with a high relapse rate despite intensive treatment. TRPA1 is a pain-sensing ion channel with downstream impacts on proliferative and pro-apoptotic pathways. Here, we evaluated TRPA1 expression in NB and performed pharmacological inhibition in preclinical models to assess its potential as a therapeutic target in NB.

Methods: TRPA1 protein levels were assessed in NB patient tumors on tissue microarrays. Bulk and single-cell gene expression data were retrieved from publicly available databases. The effects of three TRPA1 inhibitors (AP-18, A967079, and Bay 390) on NB cell viability and cell death were evaluated using NB patient-derived xenograft (PDX)-derived organoids. In vivo testing was performed in a MYCN-amplified NB PDX model. Drug combination testing was performed using combination or sequential treatments and evaluated using drug synergy scores.

Results: TRPA1 is widely expressed in NB patient tumors and preclinical patient-derived NB models. Pharmacological TRPA1 inhibition decreased NB cell viability and increased cell death. In vivo TRPA1 inhibition alone did not significantly affect NB tumor growth. Pretreatment with TRPA1 inhibition prior to chemotherapy resulted in synergistic effects in vitro.

Conclusions: TRPA1 is expressed in NB tumors, and pharmacological TRPA1 inhibition can be effective in vitro and synergistic when used as pretreatment to chemotherapy. However, the tested inhibitors did not show in vivo efficacy, at least as monotherapy.

Keywords: TRPA1; chemotherapy; neuroblastoma.

PubMed Disclaimer

References

    1. K. K. Matthay, J. M. Maris, G. Schleiermacher, et al., “Neuroblastoma,” Nature Reviews Disease Primers 2, no. 1 (2016): 16078.
    1. V. Smith and J. Foster, “High‐Risk Neuroblastoma Treatment Review,” Children 5, no. 9 (2018): 114.
    1. S. B. Whittle, V. Smith, E. Doherty, S. Zhao, S. McCarty, and P. E. Zage, “Overview and Recent Advances in the Treatment of Neuroblastoma,” Expert Review of Anticancer Therapy 17, no. 4 (2017): 369–386.
    1. J. M. Maris, “Recent Advances in Neuroblastoma,” New England Journal of Medicine 362, no. 23 (2010): 2202–2211.
    1. J. Karlsson, A. Valind, L. Holmquist Mengelbier, et al., “Four Evolutionary Trajectories Underlie Genetic Intratumoral Variation in Childhood Cancer,” Nature Genetics 50, no. 7 (2018): 944–950.

LinkOut - more resources